Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Kallikrein-related peptidases are activators of the CC chemokine CCL14.

Grünberg M, Quandt D, Cynis H, Demuth HU, Kinderman A, Magdolen V, Forssmann WG, Seliger B, Mägert HJ.

Eur J Immunol. 2018 Jul 20. doi: 10.1002/eji.201747452. [Epub ahead of print]

PMID:
30028015
2.

Tumor-dependent effects of proteoglycans and various glycosaminoglycan synthesizing enzymes and sulfotransferases on patients' outcome.

Subbarayan K, Seliger B.

Curr Cancer Drug Targets. 2018 Jul 6. doi: 10.2174/1568009618666180706165845. [Epub ahead of print]

PMID:
29984655
3.

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Steven A, Seliger B.

Breast Care (Basel). 2018 Mar;13(1):16-21. doi: 10.1159/000486585. Epub 2018 Feb 2. Review.

PMID:
29950962
4.

Immunotherapy of Breast Cancer.

Seliger B.

Breast Care (Basel). 2018 Mar;13(1):5-6. doi: 10.1159/000486927. Epub 2018 Feb 13. No abstract available.

5.

Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Subbarayan K, Leisz S, Wickenhauser C, Bethmann D, Massa C, Steven A, Seliger B.

Oncoimmunology. 2018 Jan 16;7(4):e1373233. doi: 10.1080/2162402X.2017.1373233. eCollection 2018.

PMID:
29632715
6.

Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma.

Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B.

J Transl Med. 2018 Feb 28;16(1):40. doi: 10.1186/s12967-018-1407-9.

7.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. No abstract available.

8.

Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation.

Lennicke C, Rahn J, Wickenhauser C, Lichtenfels R, Müller AS, Wessjohann LA, Kipp AP, Seliger B.

Oncotarget. 2017 Nov 23;9(1):539-552. doi: 10.18632/oncotarget.22640. eCollection 2018 Jan 2.

9.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. Erratum in: Immunity. 2018 Feb 20;48(2):396-398.

PMID:
29329948
10.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

PMID:
29301752
11.

Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue.

Polovic M, Dittmar S, Hennemeier I, Humpf HU, Seliger B, Fornara P, Theil G, Azinovic P, Nolze A, Köhn M, Schwerdt G, Gekle M.

Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27.

PMID:
29282485
12.

The tumor microenvironment: Thousand obstacles for effector T cells.

Massa C, Seliger B.

Cell Immunol. 2017 Dec 8. pii: S0008-8749(17)30223-X. doi: 10.1016/j.cellimm.2017.12.004. [Epub ahead of print]

PMID:
29249298
13.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14.

14.

Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin.

Jasinski-Bergner S, Büttner M, Quandt D, Seliger B, Kielstein H.

Obes Facts. 2017;10(6):569-583. doi: 10.1159/000481732. Epub 2017 Dec 6.

15.

The role of the miR-148/-152 family in physiology and disease.

Friedrich M, Pracht K, Mashreghi MF, Jäck HM, Radbruch A, Seliger B.

Eur J Immunol. 2017 Dec;47(12):2026-2038. doi: 10.1002/eji.201747132. Epub 2017 Sep 29. Review.

PMID:
28880997
16.

Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors.

Seliger B.

Cytokine Growth Factor Rev. 2017 Aug;36:49-56. doi: 10.1016/j.cytogfr.2017.07.001. Epub 2017 Jul 13. Review.

PMID:
28739030
17.

Multiparametric immune profiling in HPV- oral squamous cell cancer.

Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA.

JCI Insight. 2017 Jul 20;2(14). pii: 93652. doi: 10.1172/jci.insight.93652. [Epub ahead of print]

18.

"Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.

Seliger B.

Cancer Immunol Immunother. 2017 Nov;66(11):1497-1503. doi: 10.1007/s00262-017-2037-4. Epub 2017 Jul 10. No abstract available.

PMID:
28695228
19.

Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.

Lennicke C, Rahn J, Bukur J, Hochgräfe F, Wessjohann LA, Lichtenfels R, Seliger B.

Oncoimmunology. 2016 Dec 21;6(6):e1259049. doi: 10.1080/2162402X.2016.1259049. eCollection 2017.

20.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

PMID:
28655789
21.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

22.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
23.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
24.

Immunotherapy for metastatic renal cell carcinoma.

Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B.

Cochrane Database Syst Rev. 2017 May 15;5:CD011673. doi: 10.1002/14651858.CD011673.pub2. Review.

PMID:
28504837
25.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.

Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Review.

26.

High constitutive B7-H3 expression on human keratinocytes supports T cell immunity.

Quandt D, Fiedler E, Müller A, Marsch WC, Seliger B.

J Dermatol Sci. 2017 Jul;87(1):82-85. doi: 10.1016/j.jdermsci.2017.02.287. Epub 2017 Apr 11. No abstract available.

PMID:
28465042
27.

Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds.

Rahn J, Lennicke C, Kipp AP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B.

Proteomics. 2017 Jun;17(11). doi: 10.1002/pmic.201600486.

PMID:
28409884
28.

Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.

Eichmüller SB, Osen W, Mandelboim O, Seliger B.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx034. Review.

PMID:
28383653
29.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

30.

HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Seliger B, Kloor M, Ferrone S.

Oncoimmunology. 2017 Feb 6;6(2):e1171447. doi: 10.1080/2162402X.2016.1171447. eCollection 2017. Review.

31.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

32.

Methionine and seleno-methionine type peptide and peptoid building blocks synthesized by five-component five-center reactions.

Kaluđerović GN, Abbas M, Kautz HC, Wadaan MA, Lennicke C, Seliger B, Wessjohann LA.

Chem Commun (Camb). 2017 Mar 28;53(26):3777-3780. doi: 10.1039/c7cc00399d.

PMID:
28304024
33.

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients.

Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, Seliger B.

Oncotarget. 2017 Mar 28;8(13):21212-21228. doi: 10.18632/oncotarget.15064.

34.

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion.

Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA.

Oncotarget. 2017 Jan 3;8(1):1953-1954. doi: 10.18632/oncotarget.14438. No abstract available.

35.

Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.

Seliger B.

HLA. 2016 Nov;88(5):213-220. doi: 10.1111/tan.12898. Epub 2016 Sep 22. Review.

PMID:
27659281
36.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M.

Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15.

37.

HLA-E expression and its clinical relevance in human renal cell carcinoma.

Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A.

Oncotarget. 2016 Oct 11;7(41):67360-67372. doi: 10.18632/oncotarget.11744.

38.

Individual effects of different selenocompounds on the hepatic proteome and energy metabolism of mice.

Lennicke C, Rahn J, Kipp AP, Dojčinović BP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B.

Biochim Biophys Acta. 2017 Jan;1861(1 Pt A):3323-3334. doi: 10.1016/j.bbagen.2016.08.015. Epub 2016 Aug 24.

PMID:
27565357
39.

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2016 Aug 9;7(32):52061-52084. doi: 10.18632/oncotarget.10474.

40.

Checkpoint Inhibitors and Their Application in Breast Cancer.

Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B.

Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review.

41.

HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins.

Reches A, Nachmani D, Berhani O, Duev-Cohen A, Shreibman D, Ophir Y, Seliger B, Mandelboim O.

J Immunol. 2016 Jun 15;196(12):4967-76. doi: 10.4049/jimmunol.1501550. Epub 2016 May 18.

42.

Role of microRNAs on HLA-G expression in human tumors.

Seliger B.

Hum Immunol. 2016 Sep;77(9):760-3. doi: 10.1016/j.humimm.2016.04.006. Epub 2016 Apr 30. Review.

PMID:
27142884
43.

Harnessing the immune system for the treatment of melanoma: current status and future prospects.

Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D.

Expert Rev Clin Immunol. 2016 Aug;12(8):879-93. doi: 10.1080/1744666X.2016.1176529. Epub 2016 May 3. Review.

PMID:
27070898
44.

"Tumor immunology meets oncology" (TIMO) XI, May 22-23, 2015, Halle/Saale, Germany.

Quandt D, Seliger B.

Cancer Immunol Immunother. 2016 May;65(5):625-30. doi: 10.1007/s00262-016-1833-6. Epub 2016 Apr 8. No abstract available.

PMID:
27060001
45.

Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma.

Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, Braun J, Wach S, Wullich B, Spath V, Wang E, Marincola FM, Mandelboim O, Hartmann A, Seliger B.

Oncotarget. 2016 May 3;7(18):26866-78. doi: 10.18632/oncotarget.8567.

46.

Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma.

Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B.

J Transl Med. 2016 Apr 5;14:85. doi: 10.1186/s12967-016-0828-6. Review. Erratum in: J Transl Med. 2018 Feb 28;16(1):40.

47.

Disentangling the relationship between tumor genetic programs and immune responsiveness.

Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. Review.

PMID:
26967649
48.

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion.

Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA.

Oncotarget. 2016 Apr 12;7(15):20410-24. doi: 10.18632/oncotarget.7804. Erratum in: Oncotarget. 2017 Jan 3;8(1):1953-1954.

49.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.

Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV.

Oncoimmunology. 2015 Jul 25;5(1):e1052213. eCollection 2016.

50.

Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target.

Steven A, Seliger B.

Oncotarget. 2016 Jun 7;7(23):35454-65. doi: 10.18632/oncotarget.7721. Review.

Supplemental Content

Loading ...
Support Center